{"transactions":[{"id":4638434,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-10-09T16:57:06.000Z","date":"2026-10-08","kind":"exercise","planned":false,"acquired":false,"shares":4483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025."}],"balance_after":4484,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4483},"source":{"system":"sec-edgar","filing":"0001437749-26-032421","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1741968/000143774926032421/rdgdoc.xml","form_type":"4"}},{"id":4638433,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-10-09T16:57:06.000Z","date":"2026-10-08","kind":"sale","planned":false,"acquired":false,"shares":2202,"price":36.69,"value":80791.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":4561,"source":{"system":"sec-edgar","filing":"0001437749-26-032421","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741968/000143774926032421/rdgdoc.xml","form_type":"4"}},{"id":4638432,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-10-09T16:57:06.000Z","date":"2026-10-08","kind":"exercise","planned":false,"acquired":true,"shares":4483,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":6763,"source":{"system":"sec-edgar","filing":"0001437749-26-032421","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741968/000143774926032421/rdgdoc.xml","form_type":"4"}},{"id":921848,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T22:16:53.000Z","date":"2026-01-31","kind":"grant","planned":false,"acquired":true,"shares":32609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029."}],"balance_after":32609,"derivative":{"underlying":"Ordinary Shares","underlying_shares":32609},"source":{"system":"sec-edgar","filing":"0001437749-26-002841","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926002841/rdgdoc.xml","form_type":"4"}},{"id":1020831,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-10-09T17:37:33.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":false,"shares":4483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025."}],"balance_after":8967,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4483},"source":{"system":"sec-edgar","filing":"0001437749-25-030772","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925030772/rdgdoc.xml","form_type":"4"}},{"id":1020830,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-10-09T17:37:33.000Z","date":"2025-10-08","kind":"sale","planned":false,"acquired":false,"shares":2203,"price":16.85,"value":37120.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units."}],"balance_after":2280,"source":{"system":"sec-edgar","filing":"0001437749-25-030772","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925030772/rdgdoc.xml","form_type":"4"}},{"id":1020829,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-10-09T17:37:33.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":true,"shares":4483,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":4483,"source":{"system":"sec-edgar","filing":"0001437749-25-030772","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925030772/rdgdoc.xml","form_type":"4"}},{"id":1388618,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-09T20:22:54.000Z","date":"2024-10-08","kind":"grant","planned":false,"acquired":true,"shares":74142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/3 of the shares underlying the stock option will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027."}],"balance_after":74142,"derivative":{"exercise_price":13.11,"expiration_date":"2034-10-08","underlying":"Ordinary Shares","underlying_shares":74142},"source":{"system":"sec-edgar","filing":"0001415889-24-024932","document":"form4-10092024_081051.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000141588924024932/form4-10092024_081051.xml","form_type":"4"}},{"id":1388617,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-10-09T20:22:54.000Z","date":"2024-10-08","kind":"grant","planned":false,"acquired":true,"shares":13450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3 of the shares underlying the restricted stock units will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"1/3 of the shares underlying the restricted stock units will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027."}],"balance_after":13450,"derivative":{"underlying":"Ordinary Shares","underlying_shares":13450},"source":{"system":"sec-edgar","filing":"0001415889-24-024932","document":"form4-10092024_081051.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000141588924024932/form4-10092024_081051.xml","form_type":"4"}},{"id":1953655,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-14T12:30:09.000Z","date":"2023-03-13","kind":"purchase","acquired":true,"shares":10000,"price":1.9593,"value":19593.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.95 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-23-008288","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563577/000089924323008288/doc4.xml","form_type":"4"}},{"id":1986145,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-28T23:57:35.000Z","date":"2023-02-25","kind":"grant","acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023."}],"balance_after":185000,"derivative":{"exercise_price":1.78,"expiration_date":"2033-02-24","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0000899243-23-006470","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563577/000089924323006470/doc4.xml","form_type":"4"}},{"id":2359392,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-02T21:05:54.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 28, 2022."}],"balance_after":135000,"derivative":{"exercise_price":2.24,"expiration_date":"2032-02-27","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0000899243-22-008583","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563577/000089924322008583/doc4.xml","form_type":"4"}},{"id":2891876,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-28T21:05:27.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in equal monthly installments over a four year period commencing January 26, 2021."}],"balance_after":82500,"derivative":{"exercise_price":11.99,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0000899243-21-003614","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563577/000089924321003614/doc4.xml","form_type":"4"}},{"id":3290599,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-04T23:02:44.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":74435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in equal monthly installments over a four year period commencing January 31, 2020."}],"balance_after":74435,"derivative":{"exercise_price":14.84,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":74435},"source":{"system":"sec-edgar","filing":"0000899243-20-002869","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563577/000089924320002869/doc4.xml","form_type":"4"}},{"id":3376140,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2019-11-09T00:19:44.000Z","date":"2019-11-06","kind":"grant","acquired":true,"shares":229513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vests and becomes exercisable with respect to 25% on October 21, 2020 with the remaining shares vesting and becoming exercisable in equal monthly installments over a three year period thereafter."}],"balance_after":229513,"derivative":{"exercise_price":12,"expiration_date":"2029-11-05","underlying":"Common Stock","underlying_shares":229513},"source":{"system":"sec-edgar","filing":"0000899243-19-027034","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563577/000089924319027034/doc4.xml","form_type":"4"}},{"id":3619152,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-03-04T22:30:25.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of shares subject to the option shall vest on February 28, 2020 (the \"Initial Vesting Date\"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":44000,"derivative":{"exercise_price":11.32,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001209191-19-015811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919119015811/doc4.xml","form_type":"4"}},{"id":3843349,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":67955,"kind":"person","name":"Degnan Chris","position":1,"cik":"0001741968","reported_name":"Degnan Chris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-08-15T20:47:57.000Z","date":"2018-06-19","kind":"purchase","acquired":true,"shares":3000,"price":15,"value":45000.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-18-046825","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000120919118046825/doc4.xml","form_type":"4"}}]}